Welcome To Wheezing.com

Featured

Wheezing.com was created to be a quick-reference resource for online viewers. Visitors can come here and try to define different issues related to wheezing and wheezing conditions. The most common ailments that cause wheezing are asthma, allergies, bronchitis, and emphysema. We also have additional conditions listed throughout the website. Please feel free to view our pages. We hope you will find value here at wheezing.com.

Our Conditions and Treatment section provides a wide array of information related to breathing and wheezing matters including:

Allergies, Analphylaxis, Asthma, Bronchitis, COPD, Emphysema, Heart Failure, Occupational Lung Disorders, RADS, Second Hand Smoke, and much more.

In addition, please visit our wheezing resources for useful web links to a variety of breathing and wheezing related resources.

For a complete tour of the Wheezing.com website, view our site map.

EPA Plan Will Reduce Pollution and Improve Visibility in Texas, Oklahoma – Big Country Homepage


Big Country Homepage

EPA Plan Will Reduce Pollution and Improve Visibility in Texas, Oklahoma
Big Country Homepage
Studies show that fine particles penetrate deeply into sensitive parts of the lungs, where they can worsen respiratory diseases, such as emphysema and bronchitis, and can aggravate existing heart disease. Airborne fine particles are linked to increased ...

and more »

Tarkanian scheduled for release from Las Vegas hospital after treatment for … – Fox News


Tarkanian scheduled for release from Las Vegas hospital after treatment for ...
Fox News
LAS VEGAS – Family members say Hall of Famer Jerry Tarkanian is due to head home from a Las Vegas hospital after treatment for pneumonia. Amy Tarkanian says her 84-year-old father-in-law is scheduled for release Monday afternoon from Valley ...

and more »

GSK Finishes Patient Enrollment For First “Real-World” COPD Study – Lung Disease News


GSK Finishes Patient Enrollment For First “Real-World” COPD Study
Lung Disease News
The Salford Lung Study will bring together GSK and other local healthcare providers to analyze Relvar Ellipta compared with other COPD therapies in 2,800 COPD patients who will be given daily doses of the drug for a year. The phase 3 open-label study ...